Comparative proteomic analysis of normal and tumor stromal cells by tissue on chip based mass spectrometry (toc-MS)
© Escher et al; licensee BioMed Central Ltd. 2010
Received: 3 December 2009
Accepted: 28 January 2010
Published: 28 January 2010
In carcinoma tissues, genetic and metabolic changes not only occur at the tumor cell level, but also in the surrounding stroma. This carcinoma-reactive stromal tissue is heterogeneous and consists e.g. of non-epithelial cells such as fibroblasts or fibrocytes, inflammatory cells and vasculature-related cells, which promote carcinoma growth and progression of carcinomas. Nevertheless, there is just little knowledge about the proteomic changes from normal connective tissue to tumor stroma. In the present study, we acquired and analysed specific protein patterns of small stromal sections surrounding head and neck cell complexes in comparison to normal subepithelial connective tissue. To gain defined stromal areas we used laser-based tissue microdissection. Because these stromal areas are limited in size we established the highly sensitive 'tissue on chip based mass spectrometry' (toc-MS). Therefore, the dissected areas were directly transferred to chromatographic arrays and the proteomic profiles were subsequently analysed with mass spectrometry. At least 100 cells were needed for an adequate spectrum. The locating of differentially expressed proteins enables a precise separation of normal and tumor stroma. The newly described toc-MS technology allows an initial insight into proteomic differences between small numbers of exactly defined cells from normal and tumor stroma.
Carcinoma tissue does not only consist of tumor cells but also of fibroblasts, endothelial cells or vascular structures, and inflammatory cells forming the so-called desmoplastic stroma reaction or supportive tumor stroma. Many steps in carcinoma development e.g. proliferation, angiogenesis, invasion and metastasis are promoted by microenvironmental factors produced by these stromal cells. It is well known that the reciprocal interactions between tumor and stroma cells, i.e., cancer associated fibroblasts (CAF), tumor endothelial cells (TEC) and tumor associated macrophages (TAM) result in tumor progression. The close vicinity of CAFs to the cancer cells enhance tumor growth by secreting growth factors like transforming growth factor beta (TGF beta), matrix degrading enzymes like matrix metalloproteinases (MMP) and angiogenic factors such as vascular endothelial growth factors (VEGF) . The investigation of those microenvironmental factors at the proteomic level requires a technical workflow that enables the isolation of small defined areas of stroma on the one hand and a sufficient high sensitivity to analyse these small amounts of cells on the other hand. One part of this attempt is the laser-based tissue microdissection . Hereby, small areas of interest can be easily separated from the remaining tissue and further analyzed with genomic or proteomic approaches. The second prerequisite for the proteomic analysis of stromal cells is a highly sensitive detection technique. Gel-based techniques do not meet this requirement but mass spectrometry by MALDI (matrix assisted laser desorption and ionization) seems to be a better choice as shown in several studies using microdissected tissue [2, 3]. Using affinity chromatographic surfaces SELDI (surface enhanced laser desorption and ionization) offers the highest sensitivity - but with low resolution - and is a commonly used tool to investigate differentially expressed proteins in body fluids, cells and tissue [4–9]. In general, SELDI is useful to compare crude protein lysates with a high sensitivity; MALDI, in contrast, displays a higher resolution which is useful for the identification of proteins. So far, after microdissection about 3000-5000 cells are needed to receive an adequate proteomic profile. Nevertheless, it is tedious to reach even this cell number from small stromal areas within a tumor. Therefore, the purpose of this study was to develop and refine a proteomic technique which is sensitive enough to analyse as few as a hundred microdissected cells.
Microdissection of stroma from normal and tumor tissue
All head and neck tumor samples (n = 14) and normal controls (n = 14) were obtained after surgical resection at the ENT (Ear, Nose, Throat) Department of the University Hospital Jena; they had been collected fresh, snap frozen in liquid nitrogen, and were stored at -80°C. Tumor specimen were categorized to the WHO classification criteria . Ethical approval was obtained from the local Research Ethic Committee.
Applying microdissected tissue onto ProteinChip arrays and mass spectrometric analysis
A Q10 ProteinChip array (strong anion exchanger; BioRad) was activated (see ) and wetted with 0.5 μl lysis buffer (100 mM Na-phosphate (pH 7.5), 5 mM EDTA, 2 mM MgCl2, 3 mM 2-β-mercaptoethanol, 0.1% CHAPS, 500 μM leupeptine, and 0.1 mM PMSF). Under a stereo microscope (Stemi 2000c, Zeiss) the tissue section was placed on the spot of the ProteinChip array. Tissue lysis on spot was performed for 1.5 h at 4°C in a humidity chamber. After lysis and incubation the spots were washed three times with 5 μl of a washing/binding buffer (100 mM Tris-buffer, pH 8.5 with 0.02% Triton X-100) and rinsed 2 times with water. 2 × 0.5 μl sinapinic acid (saturated solution in 0.5% TFA/50% acetonitrile) was applied as matrix on the dried spots. The matrix which co-crystallizes with proteins absorbs the laser energy and transfers part of its charge to the proteins. Mass analysis was performed in a ProteinChip Reader (PCS 4000, Ciphergen Biosystems Inc, Fremont, CA) with a manual data collection protocol.
Because cells were microdissected, placed and lysed directly on the spot of the ProteinChip array under control of a stereo microscope, we named this technique 'tissue on chip based mass spectrometry' (toc-MS). Areas of different size and cell number were tested. At least 100 cells were needed for an adequate spectrum. For the analysis of the normal and tumor samples 300 cells were dissected for more robust results. Compared to the SELDI standard procedure the sensitivity is increased at least tenfold and, because no protein lysis and extraction is needed, time of analysis is shorter by half. In contrast to MALDI imaging, which allows to analyse spatial resolved protein spectra over tissue sections and other mass spectrometry techniques, the SELDI characteristic affinity chromatograhic chip surfaces allow a more quantitative analysis of proteins.
Bioinformatic analysis of mass spectrometry data
The 7,477 Da peak is significantly higher expressed (P = 0.0003) in tumor stroma, while the 80,044 Da peak (P = 0.0009) is reduced in tumor stroma. An initial data base search according molecular size offered for the 7,477 Da mass the beta defensin 119 (UniProtKB/Swiss-Prot Q8N690 Chain: 22-84: 7493 Da). Human beta-defensines (HBD) are cationic, antimicrobial peptides produced by epithelial cells and show altered inconsistent expression in cancers [12, 13]. Analyses of their expression in tumor stroma are not published yet. For the fibroblast growth factor 23 only a role in phosphate homeostasis and related disorders is known . The protein with a molecular mass of 80,044 Da is equivalent in size to the unphosphorylated ski oncogene (UniProtKB/Swiss-Prot P12755, 80,005 Da) which was discovered as oncogene by its ability to transform chicken embryo fibroblasts upon overexpression. But in newer studies also anti-oncogenic activities are discussed (for review see ).
In conclusion, we applied toc-MS successfully to analyse a few hundred stromal cells quantitatively and to differentiate between those stromal areas near to tumor and to normal epithelium. An exact identification of these proteins with tryptic digestion and tandem MS is in progress. Ongoing research focuses on down-scaling the procedure to a higher sensitivity.
tissue on chip based mass spectrometry
matrix-assisted laser desorption and ionization
surface enhanced desorption and ionization
cancer associated fibroblasts
tumor endothelial cells
tumor associated macrophages
laser microdissection and pressure catapulting.
The CUCA is supported by the German Federal Ministry of Education and Research (BMBF) and the Interdisciplinary Center of Clinical Research (IZKF), Jena.
- Hofmeister V, Schrama D, Becker JC: Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother. 2008, 57: 1-17. 10.1007/s00262-007-0365-5.View ArticlePubMedGoogle Scholar
- von Eggeling F, Melle C, Ernst G: Microdissecting the proteome. Proteomics. 2007, 7: 2729-2737. 10.1002/pmic.200700079.View ArticlePubMedGoogle Scholar
- Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nature Reviews Cancer. 2003, 3: 267-275. 10.1038/nrc1043.View ArticlePubMedGoogle Scholar
- Kriegova E, Melle C, Kolek V, Hutyrova B, Mrazek F, Bleul A, du Bois RM, von Eggeling F, Petrek M: Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. American Journal of Respiratory and Critical Care Medicine. 2006, 173: 1145-1154. 10.1164/rccm.200507-1126OC.View ArticlePubMedGoogle Scholar
- Busch A, Michel S, Hoppe C, Driesch D, Claussen U, von Eggeling F: Proteome Analysis of Maternal Serum Samples for Trisomy 21 Pregnancies Using ProteinChip Arrays and Bioinformatics. J Histochem Cytochem. 2005, 53: 341-343. 10.1369/jhc.4B6377.2005.View ArticlePubMedGoogle Scholar
- Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF: Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers. 2001, 17: 301-307.PubMed CentralView ArticlePubMedGoogle Scholar
- Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002, 359: 572-577. 10.1016/S0140-6736(02)07746-2.View ArticlePubMedGoogle Scholar
- Driemel O, Murzik U, Escher N, Melle C, Bleul A, Dahse R: Protein profiling of oral brush biopsies: S100A8 and S100A9 can differentiate between normal, premalignant and tumor cells. Proteomics - Clinical Applications. 2007, 1: 486-493. 10.1002/prca.200600669.View ArticlePubMedGoogle Scholar
- Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, Thieme H, Kaufmann R, Felix K, Friess HM, Settmacher U, Hommann M, Richter KK, Daffner W, Täubig H, Manger T, Claussen U, von Eggeling F: Protein Profiling of Microdissected Pancreas Carcinoma and Identification of HSP27 as a Potential Serum Marker. Clin Chem. 2007Google Scholar
- Barnes L, Eveson JW, Reichart P, Sidransky D: World Health Organization classification of tumours. Pathology & genetics. Head and neck tumours. 2005, International Agency for Research on Cancer (IARC). Lyon, France: IARC PressGoogle Scholar
- Melle C, Ernst G, Schimmel B, Bleul A, Koscielny S, Wiesner A, Bogumil R, Möller U, Osterloh D, Halbhuber KJ, von Eggeling F: A Technical Triade for Proteomic Identification and Characterization of Cancer Biomarkers. Cancer Res. 2004, 64: 4099-4104. 10.1158/0008-5472.CAN-03-3807.View ArticlePubMedGoogle Scholar
- Joly S, Compton LM, Pujol C, Kurago ZB, Guthmiller JM: Loss of human beta-defensin 1, 2, and 3 expression in oral squamous cell carcinoma. Oral Microbiology and Immunology. 2009, 24: 353-360. 10.1111/j.1399-302X.2009.00512.x.View ArticlePubMedGoogle Scholar
- Droin N, Hendra JB, Ducoroy P, Solary E: Human defensins as cancer biomarkers and antitumour molecules. Journal of Proteomics. 2009, 72: 918-927. 10.1016/j.jprot.2009.01.002.View ArticlePubMedGoogle Scholar
- Ramon I, Kleynen P, Body JJ, Karmali R: Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol. 2009Google Scholar
- Deheuninck J, Luo KX: Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Research. 2009, 19: 47-57. 10.1038/cr.2008.324.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.